📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-26 16:37
298 analysed today
FollowTelegram
298
Today
149,699
All-time analysed
42,924
Positive
6,662
Negative
91,432
Neutral
8,613
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
4 announcements match the current filters (relevance ≥ 5).
Centenial Surgical Suture Alerts BSE & SEBI Over Suspected Share Price Manipulation
Centenial Surgical Suture Ltd has formally approached the surveillance departments of BSE and SEBI, requesting an urgent investigation into abnormal price movements and suspected scrip manipulation. The company highlighted that single-share trades have repeatedly triggered 4.64% to 4.99% upper circuit moves on days including August 18, 21, and 26, 2026, despite no material business developments. Management explicitly clarified that the company, promoters, and directors have no involvement in these trades and submitted trading logs alleging synchronized nationwide buying.
Confidence: HIGH
What changedThe company formally petitioned BSE and SEBI to probe suspected artificial price rigging executed via repetitive single-share trades.
Why it mattersConfirms that recent stock price gains are unsupported by corporate fundamentals, warning retail investors against abnormal liquidity and potential price distortion.
Traded volume on Aug 26, 2026: 1 equity shareScrip price on Aug 26, 2026: Rs.97.49Traded volume on Aug 21, 2026: 1 equity shareScrip price on Aug 21, 2026: Rs.98.69Market capitalization: Rs 34 Cr
📅 Short termStock may face heightened surveillance measures or trading restrictions from the exchange, leading to increased volatility or locked circuits.
📈 Long termLimited operational impact, but critical for regulatory standing and market integrity of the scrip.
⚠ Risk flags
- High illiquidity and price manipulation risk evidenced by 1-share circuit moves
- Risk of severe exchange surveillance actions (e.g., ESM/GSM/trading curbs)
- Subdued fundamental earnings (TTM net loss of Rs -1 Cr)
Key Highlights
On August 26, 2026, a 1-share trade moved the price up 4.64% to Rs 97.49.
On August 21, 2026, a 1-share trade increased the price by 4.99% to Rs 98.69.
On August 18, 2026, a single-share trade drove the share price to Rs 90.00.
Company submitted investor trading logs from December 2025 to February 2026 to substantiate claims of coordinated trading.
👀 What to Watch
Track whether BSE/SEBI initiates regulatory action or places the scrip under Enhanced Surveillance Measure (ESM) or Additional Surveillance Measure (ASM) frameworks.
Centenial Surgical Suture Appoints Sapna Mhatre as CFO Following Anuradha Kashikar's Resignation
Centenial Surgical Suture Ltd has announced key managerial changes effective August 14, 2026. Anuradha Kashikar, spouse of Managing Director Vijay Majrekar, has resigned from the position of Chief Financial Officer citing personal reasons. The Board has appointed Ms. Sapna Mhatre, who has been with the company since September 2001 as Chief Administrative Officer, as the new CFO. The micro-cap company currently operates with a market cap of ₹31 Cr and TTM revenue of ₹56 Cr.
Confidence: HIGH
What changedAnuradha Kashikar stepped down as CFO on August 14, 2026, replaced by internal candidate Sapna Mhatre.
Why it mattersTransitions the CFO position from a promoter-related individual to a long-serving internal executive, maintaining operational familiarity within the finance department.
Effective date: August 14, 2026New CFO tenure with company: Since September 2001Market Cap: Rs 31 Cr
📅 Short termAdministrative transition is expected to remain smooth given the new CFO's extensive tenure of over two decades at the company.
📈 Long termLimited structural impact on the commercial trajectory of the business, though professionalizing the CFO function away from direct promoter relations is a governance aspect.
⚠ Risk flags
- Transition risk in key financial reporting and compliance roles
Key Highlights
Anuradha Kashikar resigned as CFO and KMP effective August 14, 2026, citing personal reasons.
Sapna Mhatre appointed as Chief Financial Officer and KMP effective August 14, 2026.
Incoming CFO Sapna Mhatre has been in employment with the company since September 2001.
Outgoing CFO is the spouse of MD Vijay Majrekar; incoming CFO is confirmed unrelated to any director.
👀 What to Watch
Monitor upcoming quarterly financial filings to assess seamless transition and stability in financial reporting and internal accounting controls.
Centenial Surgical Q1 Turns Profitable at ₹0.74 Cr; Revenue Rises 18.6% YoY to ₹15.34 Cr
Centenial Surgical Suture reported standalone revenue of ₹15.34 cr for the quarter ended June 30, 2026, up 18.6% YoY from ₹12.94 cr in the year-ago period. Operating profit stood at ₹2.18 cr, a substantial improvement from ₹0.93 cr in the previous quarter. The company turned profitable with a net profit of ₹0.74 cr (EPS ₹2.01) compared to a net loss of ₹2.31 cr in Mar 2026 and ₹0.04 cr in Jun 2025.
Confidence: HIGH
What changedCentenial Surgical Suture approved and published its standalone unaudited financial results for the quarter ended June 30, 2026.
Why it mattersThe company demonstrated an operational and bottom-line turnaround after reporting a ₹2.20 cr net loss in FY26, relevant for a ₹31 cr market-cap company.
Q1 Revenue: ₹15.34 crQ1 Net Profit: ₹0.74 crQ1 Operating Profit: ₹2.18 crQ1 EPS: ₹2.01Q1 Revenue vs TTM Revenue: ~27.4%
📅 Short termLikely to be viewed positively in the near term driven by turnaround from sequential losses to positive EPS.
📈 Long termConsistent quarterly execution is required to build a sustained track record of profitability and improve return ratios (ROCE at 2.5%).
⚠ Risk flags
- Micro-cap liquidity risk
- Historical earnings volatility with net losses reported in FY25 and FY26
Key Highlights
Revenue from operations increased 18.6% YoY to ₹15.34 cr (vs ₹12.94 cr in Jun 2025)
Operating profit expanded to ₹2.18 cr from ₹1.23 cr in Jun 2025 and ₹0.93 cr in Mar 2026
Net profit swung to ₹0.74 cr versus a loss of ₹2.31 cr in Mar 2026 and loss of ₹0.04 cr in Jun 2025
Diluted/Basic EPS for the quarter improved to ₹2.01
👀 What to Watch
Track whether margin expansion and positive quarterly profitability can be maintained over subsequent quarters given annual net losses in FY26.
Centenial Surgical Appoints Sapna Mhatre as CFO, Approves Q1 Results and Schedules 31st AGM
Centenial Surgical Suture Ltd announced that its Board of Directors met on August 14, 2026, and approved the standalone unaudited financial results for the quarter ended June 30, 2026. The Board appointed Ms. Sapna Mhatre as the new Chief Financial Officer (KMP) effective August 14, 2026, following the resignation of Ms. Anuradha Kashikar from the CFO post. Ms. Kashikar continues as Executive Director with a proposed 3-year term extension from April 1, 2027, to March 31, 2030, subject to shareholder approval. The company's 31st Annual General Meeting is scheduled for September 28, 2026.
Confidence: HIGH
What changedAppointment of a new CFO (Sapna Mhatre) replacing Anuradha Kashikar, and board approval of Q1 FY27 financial results.
Why it mattersSeparates the Executive Director and CFO roles for improved governance while maintaining management continuity at the Rs 31 Cr market cap medical supplies maker.
CFO Effective Appointment Date: August 14, 2026ED Re-appointment Tenure: 3 years (April 1, 2027 to March 31, 2030)31st AGM Date: September 28, 2026Market Cap: Rs 31 Cr
📅 Short termNeutral impact expected as the leadership handover is internal/procedural and accompanied by regular Q1 compliance items.
📈 Long termLimited structural impact unless the new financial leadership drives improved operating margins and balance sheet optimization.
⚠ Risk flags
- Leadership transition in key financial oversight role (CFO)
- Historical earnings volatility with small revenue base (Rs 56 Cr TTM)
Key Highlights
Appointed Ms. Sapna Mhatre as Chief Financial Officer (KMP) effective August 14, 2026.
Accepted resignation of Ms. Anuradha Kashikar as CFO; approved her re-appointment as Executive Director for 3 years (April 1, 2027 to March 31, 2030).
Approved Standalone Un-Audited Financial Results along with Limited Review Report for Q1 ended June 30, 2026.
Appointed M/s. Utsav Shah & Associates, Chartered Accountants, as Internal Auditor for FY 2026-2027.
Scheduled the 31st Annual General Meeting for Monday, September 28, 2026.
👀 What to Watch
Review detailed Q1 FY27 financial disclosures and monitor shareholder approval for director re-appointments at the September 28, 2026 AGM.
